Sun Pharma gets exclusive patent licence for Vortioxetine

Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults

Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes

Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults

BioPharma’s Herceptin biosimilar Phase 3 results positive

The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile

Johnson & Johnson Vision Care receives USFDA approval for drug-eluting contact lens

Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category

Oragenics announces positive data on Covid-19 intranasal vaccine

Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters

Japan approves Keytruda plus Lenvima for two types of cancer

Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.

Prestige BioPharma’s Tuznue receives EU-GMP certification

Prestige BioPharma’s facility receives EU-GMP certification

The facility will manufacture its Herceptin biosimilar, Tuznue

Merck announces leadership team for human health business

In the interim, Deepak Khanna will lead Human Health International.

LEO Pharma appoints Brian Hilberdink President of LEO Pharma, US

Brian joins LEO Pharma from Novo Nordisk, U.S. where he served as Senior Vice President of Sales.